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ABSTRACT  
BACKGROUND: There is a medical need for new drugs in BRAF wildtype metastatic melanoma 
patients. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) with anti-tumour and anti-
angiogenic activity. 
OBJECTIVES: The primary aim of the study was to investigate the metabolic response to 
pazopanib monotherapy and pazopanib plus paclitaxel therapy in BRAF wildtype melanoma 
patients. Secondary endpoints were the early cytokine and chemokine profile and the 
histological findings. 
METHODS: Orally given pazopanib (400 mg twice a day) was administered from day 1 to 10 
and from day 14 to day 70. An intravenous infusion with paclitaxel (150mg/m2 body surface) 
was administered on days 14, 35 and 56. Metabolic response evaluation was performed before 
treatment, after treatment with pazopanib (day 10) and after treatment with pazopanib and 
paclitaxel (day 70). Skin biopsy of metastasis tissue for chemokine and cytokine expression 
analysis, histology and immunohistochemistry (CD68, CD163) evaluation and blood samples 
were taken at the same time points. 
RESULTS: 2 patients failed screening, 17 were dosed. Out of 67 adverse events, 9 (13%) were 
grade 3 or 4. Five of 14 evaluable patients had a partial metabolic response at day 10 under 
pazopanib monotherapy. Response rate at day 70 under combined pazopanib-paclitaxel 
treatment was 0%. Immunohistochemistry revealed an increase of M2-like macrophages in 
non-responders compared to responders. We observed a significant upregulation of 5 cytokines 
in responding (CXCL1, CXCL2, CXCL13, CCL22 and SPP1) versus non-responding lesions. 
Overall, the median progression-free survival was 70 days (range of 5 to 331 days), which did 
not significantly differ between responders (148 days) and non-responders (70 days; p=0.17). 
CONCLUSION: In this patient population pazopanib efficacy was limited. Response is associated 
with low M2-like macrophage density and increased expression of several chemokines. 
 
Keywords: melanoma, pazopanib, paclitaxel, cytokine, immune reaction 
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INTRODUCTION  
There has been a dramatic survival benefit in advanced melanoma based on newly developed 
therapies in the last years including targeted therapies and antibodies against negative 
modulators of immunological checkpoints 1-4 
For patients with an activating BRAF V600 mutation (estimated prevalence: 40-60% 5) a BRAF-
inhibitor alone or in combination with a MEK inhibitor therapy may be effective 6-8. In a phase 
III study, vemurafenib improved the median overall survival significantly in patients with BRAF 
V600E/K mutations, compared to treatment with darcarbazine 9. Recent data also show early 
promising results for NRAS-mutated patients (estimated prevalence: 20-30% 10) for the 
treatment with the MEK-inhibitor binimetinib 
(http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-
newsArticle&ID=2122959); www.clinicaltrials.gov; Reference number NCT: 01763164) 11,12. For 
BRAF and NRAS wildtype patients (i.e. double wildtype patients) there are fewer small molecule 
pathway inhibitor possibilities. Interference in the mitogen activated protein kinase (MAPK) 
pathway using single or combined molecular targeted therapies is promising but challenging 13. 
A systematic literature review of the multi-target tyrosine kinase inhibitor (TKI) sorafenib did 
not reveal an explicit benefit in the treatment of melanoma 14. Sorafenib did not show 
convincing efficacy in a phase III melanoma clinical trial 15. However, in a study previously 
performed in our department, responders to sorafenib showed a clear upregulation of 
interferon y (IFNy) – stimulated immune response genes in profiled metastases 16. 
 
Pazopanib is an orally-bioavailable, adenosine tri-phosphate (ATP)-competitive tyrosine kinase 
inhibitor of the vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3, of the 
platelet derived growth factor receptor (PDGFR) -α and -β and c-Kit, showing   
selectivity for VEGFRs. VEGFR is highly expressed by melanoma cells and is suggested to be 
associated with disease progression 17. The VEGF-pathway is a key regulator in angiogenesis. In 
addition, it modulates the function of T cells, suppressive immune cells and stroma in the 
tumour microenvironment, leading to an immunosuppressive state 18. Pazopanib offers the 
potential to impact on tumour vasculature and the host immune functions. Currently, the drug is 
approved by the European Medicines Agency for the treatment of renal cell carcinoma and soft 
tissue sarcoma 19. It has also shown antitumour activity in ovarian cancer and non-small cell 
lung carcinoma 20. 
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Cytotoxic chemotherapy (single agent or combination) has been used for many years without 
evidence to improve overall survival in advanced melanoma patients. Response rates are 
typically less than 20% and the median response duration is a maximum of six months 21. The 
mean response rate for paclitaxel in advanced melanoma patients as a single agent is estimated 
to be approximately 17% (22-24). Therefore, chemotherapy is currently limited to third line or 
palliative settings. Nevertheless combination of a cytotoxic chemotherapy with TKI often show 
superiority to single agent treatment 25.  
Fruehauf et al (26) performed a clinical trial investigating the combination of pazopanib with 
paclitaxel for patients with advanced and unresectable metastatic melanoma with promising 
results. We initiated an open-label, investigator-initiated study for pazopanib-naïve and BRAF 
wildtype metastatic melanoma patients, with the aim to evaluate the early response to 
pazopanib.  Furthermore, we focused on the cytokine and chemokine profile of the target 
tumour lesion. We postulate that pazopanib has secondary immunomodulatory properties and 
influences different aspects of the anti-tumour immune response.  
 
PATIENTS, MATERIALS AND METHODS 
 
Study protocol 
The study protocol was developed by RD and JM and approved by the institutional and regional 
ethical committee (Reference number 2012-0104) and Swissmedic (Authorization number 
60326). The trial was registered in www.clinicaltrial.gov (Reference number NCT 01666418). It 
was conducted in accordance with the ethical principles of the Declaration of Helsinki and in 
according to good clinical practice. 
Patients and Study design 
The study was an investigator-initiated, open-label, pilot study performed at the Department of 
Dermatology, University Hospital Zurich, Switzerland, between June 2012 and December 2013. 
Patients with unresectable melanoma stage III and stage IV, according to current AJCC staging 
system 27, with histologically confirmed skin or lymph node metastases larger than 1 cm in 
diameter and measurable by Positron Emission Tomography Computed Tomography (PET/CT) 
scan, were eligible. They were recruited at the Skin Cancer Center of the University Hospital of 
Zurich. Patients had to be pazopanib-naïve but were allowed to have previous systemic, 
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targeted, and immune therapies. Patients with significant comorbidities (e.g. severe 
cardiovascular, gastrointestinal, renal, hepatic or psychiatric conditions, severe infections, 
metastatic neoplasms other than melanoma or symptomatic metastatic brain or meningeal 
disease) were excluded. All patients gave written informed consent prior to study inclusion. 
Sanger sequencing 
Each patient was sequenced for mutations in BRAF exon 15, NRAS exon 2 and 3, and cKIT exon 
9, 11, 13, 17 and 18. Primers for each exon are in Supplemental Table 1. 
Treatment 
The treatment regimen included orally administered pazopanib (Votrient®, 
GLAXOSMITHKLINE, Switzerland) 400 mg twice a day for 10 days, followed by a drug holiday of 
4 days. Pazopanib was restarted at day 14 and given until day 70 (Figure 1A). Intravenous 
paclitaxel (Taxol®, Bristol-Myers Squibb SA, Switzerland) 150mg/m2 body surface was given on 
days 14, 35 and 56. In case a patient showed disease stabilization (tumour regression or stable 
disease) at the end of the study, the study medication was continued as long as a clinical benefit 
was observed.  
Toxicity 
Adverse events were documented according to the National Cancer Institute Common 
Terminology for Criteria Adverse Events (NCI CTCAE) version 3.0 (www.cancer.gov). 
Response evaluation 
PET/CT scans with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) were performed within 28 
days prior to baseline and on day 10 and 70 with standardized adjusting. Response to 
therapy was assessed in PET/CT images using Positron Emission Tomography (PET) 
response criteria in solid tumours (PERCIST) 1.0 criteria 28,29. Complete metabolic response 
(CMR) and partial metabolic response (PMR) were considered as metabolic response; 
stable metabolic disease (SMD) and progressive metabolic disease (PMD) were evaluated 
as metabolic non-response. 
Blood sample acquisition 
Blood samples were collected at day 0, day 10 and day 70 and processed routinely in the 
laboratory of the University Hospital Zurich. Standard values for lactate dehydrogenase (LDH) 
and S100B were defined as lower or equal to the reference cut-off of 480 U/l and 0.2 μg/l, 
respectively.  
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Biopsy collection 
The investigators defined a reference metastasis (subcutaneous or lymph node metastasis, 
more than 1 centimetre in diameter) prior to the start of the study in every patient. Serial 
biopsies were taken from the opposite ends of the same tumor if larger than 2 cm or taken from 
neighbouring comparable metastases. The biopsies were performed before treatment 
(baseline), after treatment with pazopanib (day 10) and after treatment with pazopanib and 
paclitaxel (day 70) and preserved in RNAlater and cryopreservation (Ambion, Life Technologies 
Corp., Carlsbad, CA, USA) for chemokine and cytokine profiling and in formalin for 
immunohistochemistry.  
Histology and immunohistochemistry  
All tissues used for immunohistochemistry were fixed in 4% paraformaldehyde and embedded 
in paraffin. Sections were deparaffinised in xylene and rehydrated. Haematoxylin and eosin 
(H&E) staining was used to evaluate the overall morphology of the metastasis and the 
surrounding tissue. Epitope retrieval was performed in antibody-specific buffers. The following 
antibodies were used: CD68 (DAKO, Glostrup, Denmark), CD163 (DAKO, Glostrup, Denmark), 
and CD8 (DAKO, Glostrup, Denmark). Staining was performed using kits supplied by DAKO 
REAL Detection System (kit 5005). Antigen-specific antibodies were applied and visualized with 
the ChemMate detection kit (DAKO). Slides were counter-stained with H&E. Staining intensity 
for CD68 and CD163 was graded by board-certified dermato-pathologists (RD, EG). Macrophage 
density was graded in 3 levels, level 1 corresponding to lower than 30%, level 2 between 30% 
and 60% and level 3 to above 60% of total cell count. 
Chemokine and cytokine profiling and data analysis 
Tissue biopsies were evaluated by a board certified dermatopathologist to identify the tumor 
region. Biopsies with a minimum of 80% tumor area were submitted for total RNA extraction 
with the QIAGEN RNAeasy kit (Qiagen, Venlo, Netherlands). RNA purity and quality was 
determined by Nanodrop, samples were excluded if 260/230 was below 1.5 and 280/260 was 
below 1.8. cDNA was made from the RT2 HT First Strand Kit (330441; Qiagen) according to 
manufacturer's instructions. Genes were evaluated with the Human cytokine & chemokine PCR 
array (PAHS-150ZA; Qiagen) with the Viia7 system from Applied Biosystems. Fold change and P 
values were calculated by RT2 Profiler PCR Array Analysis (Qiagen). Genes were normalized to 
the three housekeeping genes on the array.  
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Statistical analysis 
Statistical analysis of the data was performed using GraphPad Prism software version 5.0 
(GraphPad Software, San Diego California USA). Statistical analysis for immunohistochemistry 
data was performed using the Mann-Whitney U Test. Comparison of Kaplan-Meier survival 
curves was performed using log-rank test. P values of less than 0.05 were considered 
statistically significant.  
 
RESULTS 
 
Patient population 
Nineteen patients were enrolled in the study. Two of them did not meet all the inclusion criteria 
or presented with exclusion criteria. Out of 17 patients included (12 male and 5 female, mean 
age:  69.8 years ± 12.0 years), 16 (94.1%) were classified as stage IV and 1 patient with 
amelanotic vulvar melanoma as stage III. One patient presented with asymptomatic brain 
metastases prior to study inclusion. The detailed patient characteristics are shown in Table 1. 
Toxicity to Pazopanib and Paclitaxel 
The median treatment duration was 62 days (minimum 5 days, maximum 70 days). 67 adverse 
events (AEs) of any grade related to the study drugs were reported in 15 of the 17 patients 
(88% of patient population). The other common AEs occurring during anti-VEGF treatment 
such as hypertension and proteinuria were not observed in this study (30-34). Only one patient 
presented with epistaxis.  
According to grade 1 or 2, 87% of all adverse events (AEs) were mild or moderate and included 
constitutional symptoms (fatigue, loss of appetite, dysgeusia and weakness), skin changes 
(alopecia, maculopapular rash), impairment of bone marrow function (anemia, leucopenia and 
neutropenia), neurological side effects (peripheral dysesthesia) and gastrointestinal side effects 
(nausea, diarrhea, constipation, elevated liver parameters).  
Nine (13%) of all the AEs were classified as serious adverse events (SAEs). The most frequently 
reported SAEs were impairment of the bone marrow function (3 cases of neutropenia grade 4) 
and liver toxicity (3 cases of elevated liver parameters grade 3). The other SAEs were severe 
fatigue, dysgeusia and wound infection.    
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Adverse drug reactions led to study discontinuation in 8 patients: 2 of them due to serious 
neutropenia, 1 patient due to fatigue, 1 patient because of pneumonia, 1 as a consequence of 
persisting dyspnea, 2 due to worsening of the general condition and 1 because of severe 
dysgeusia. 
All adverse events are summarized in Table 2. 
Metabolic response at day 10 and day 70 evaluated by PERCIST 
Fourteen of the 17 treated patients in our study were amenable to metabolic evaluation of the 
PET/CT at day 10 (under pazopanib monotherapy) (Figure 1B). Three patients were not 
evaluable due to early progression. One target lesion was selected for analysis under PERCIST 
1.0 criteria (Figure 2A). The mean SUV (Standardized uptake value) at baseline (n=17) was 16,0 
(± 9,6), at day 10 (n=14) 13,6 (± 9.5) and at day 70 (n=7) 16,5 (± 11,2).  Based on the SUV of the 
target lesions (day 10 versus day 0), we identified 5 patients with PMR under therapy with 
pazopanib (Table 3, Figure 2B). The 9 non-responders included 5 patients with SMD and 4 with 
PMD. Responders under pazopanib had a mean SUV- reduction of 67.6 % at day 10 (± 16.4), 
while non-responders had a mean SUV-increase of 17% (± 32.8) at this time. 
 
The analysis of the local response at day 70 (under therapy with pazopanib and paclitaxel) 
compared to baseline was feasible in 8 patients (3 with PMD, 3 with SMD and 2 PMR) (Figure 
2C). Local disease control rate (CMR+ PMR+ SMD) at day 10 for the 14 patients with analysable 
PET/CT came up to 71.4%. Global response rate at day 70 was 0%. Five patients presented SMD 
and continued the therapy off-study. 
Mutation status 
In the responder group, we had 3 patients with wildtype status for BRAF and NRAS. One patient 
had a c-kit mutation and one patient had NRAS mutation. The non-responder group consisted of 
6 double-wildtype patients and 3 patients with BRAF wildtype and NRAS mutation. 
Progression free survival and overall survival 
Median progression-free survival (PFS) was 70 days (range from 5 to 177 days) (Figure 3A). 
Median PFS in the local responders was longer (148.5 days) than in non-responders but was not 
significant (70 days), p=0.17. 
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Median overall survival (OS) was 208 days (range from 69 to 1073 days) (Figures 3B). Median 
OS in the local responders showed a trend to be longer than in the non-responders, 494 and 208 
days respectively, but not significant (p=0.31). 
The reason for discontinuation of the study was progression in 9 patients and adverse events in 
8 patients. 
LDH and S100 (Serum) 
Mean LDH value at time of screening (n=16) was 632 U/l ± 244 U/l, at day 10 (n=15) 739 U/l ± 
437 U/l and at day 70 (n=8) 581U/l ± 192 U/l.  The responder group had lower (not significant) 
levels of LDH compared to the non-responder group at each time point. (Figure 3C, Table 4).  
 
Mean S100 value at time of screening (n=17) was 3,4 μg/l ± 6,2 μg/l, at day 10 (n=15) 3,0 μg/l ± 
6,4 μg/l and at day 70 (n=8) 1,0 μg/l ± 1,22μg/l.  The responder group had lower (not 
significant) levels of S100 compared to the non-responder group at each time point (Figure 3D, 
Table 4). 
Biopsies (Histology) 
We analysed haematoxylin-eosin stained slides of the metastases of 4 responder and 4 non-
responder patients at day 0 and day 10. The tumour cells presented epitheloid large cell 
morphology or nested small to medium size morphology. The tumour areas showed a wide 
variation of melanin content, focal areas of necrotic cells, inflammatory infiltrates and mitotic 
figures. The intra-individual morphology of the tumour cells was similar. There were no 
consistent changes in morphology between day 0 and day 10 (Figure 4A). 
 
Biopsies (Immunohistochemistry) 
The immunohistochemical stainings of CD68/CD163 (glycoproteins, expressed on monocytes 
and tissue macrophages) served to estimate macrophage and M2-like macrophage density and 
distribution in metastatic tissue. CD8 was also evaluated to estimate cytotoxic T- cell 
infiltration. Non-responders exhibited higher frequencies of CD163 positive cells and CD8 
positive cells (day 10 versus baseline) mainly around the tumour stroma (Figure 4B). CD68 
showed a comparable staining pattern suggesting that most, if not all CD68+ cells also 
expressed CD163. 
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Biopsies (Cytokine and chemokine profiling to pazopanib treatment) 
The differential chemokine and cytokine analysis was performed on 3 responders and 3 non-
responders as the other 24 samples had Cycle threshold values below the detectable limit. 
Overall, the responders had the majority of cytokines and chemokines upregulated at day 10 
compared to baseline, while the non-responders had the majority of cytokines and chemokines 
downregulated at day 10 (Figure 5A). There were 5 out of 84 significant differentially expressed 
cytokines and chemokines between the non-responders and the responders: CXCL1, CXCL2, 
CXCL13, CCL22, and SPP1 (p < 0.05) (Figure 5B). On average, the responders had at least 0.5-
fold higher expression of these chemokines at day 10 and the non-responders had at least 2-fold 
lower expression at day 10.  
 
DISCUSSION 
 
Melanoma patients with BRAF and NRAS wildtype tumours have limited options when treated 
with targeted small molecule inhibitors. There is a dire need for new therapies for these 
patients.  Multi-target TKIs have not been well established in melanoma patients so far.  
 
PET/CT is a powerful imaging technique that - in contrast to conventional CT - demonstrates 
metabolic alterations early during a drug intervention. Selective kinase inhibitors such as 
vemurafenib induce a drastic decrease of glucose uptake 35 within 15 days after treatment 
initiation. The reduction of SUV after 3-4 weeks might help to identify patients with a prolonged 
benefit from targeted therapies 36.  
Previously, we have used PET/CT to investigate early responses during treatment with the 
multi kinase inhibitor sorafenib. It was able to identify responders already after ten days. 
Interestingly, the reduction of SUV was clearly associated with morphological and 
immunological signs of regression such as increased expression of interferon gamma 16. These 
data suggested that tumour regression induced by sorafenib is accompanied by a plethora of 
immunological processes. However, sorafenib was not successful in randomized clinical trials 
14,15,37-39 despite promising early phase results. 
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Our study was designed to investigate the metabolic response and early local immunological 
events induced by pazopanib together with paclitaxel. 
 
Pazopanib is a poorly investigated drug in metastatic melanoma. Fruehauf et al. 26 presented 
data on a phase 2 trial using pazopanib and paclitaxel in 55 melanoma patients. They reported 
an overall response rate of 33% and a median PFS of 7.7 months. A similar response rate was 
reported for patients treated in a Phase I dose escalation trial 40. We did not observe objective 
responses in our patient population that presented with several prognostic factors associated 
with poor outcome such as M1c stage, multiple distant metastases and elevated LDH and S100 
levels 41.  
 
To evaluate the contribution from the immune system during pazopanib treatment, we stained 
for CD68, CD163 and CD8. An interesting finding in our study was the higher amount of 
macrophages in the non-responders compared to the responders and the lack of CD8 cells in the 
responders but surprisingly the increase in CD8 in the non-responders. Tumour associated 
macrophages (TAMs) have been described before as tumour promoting by supporting the 
proliferation, survival and motility of cancers cells 42. This hypothesis is supported by our 
immunohistochemical findings for CD68 and CD163. CD68 is a commonly used marker in 
immunohistochemistry to identify all macrophages 43 and CD163 is used as a marker to identify 
M2-like macrophages 44. CD163 positive macrophages have been associated with TAMs 45.  
Most CD68 positive cells were also CD163 positive, suggesting a macrophage tumour supportive 
environment. We observed a higher staining intensity of CD163 positive tumour-associated 
macrophages in the non-responder group compared to responder group before treatment and 
at day 10 of pazopanib treatment; however it was not statistically significant due to the lower 
number of samples. In conjunction with the increase in CD163, CD8 positive cells were also 
increased. We suspect that the CD163 population is dampening the CD8 response. Though 
surprisingly, there was no significant increase in CD8 infiltration in the responder group, 
suggesting a CD8 independent mechanism of response. These results were confirmed in the 
qPCR results. The vast majority of cytokines and chemokines were upregulated at day 10 in the 
responders compared to the non-responders. Interferon gamma was upregulated in the 
responder group (1.0 fold upregulation versus -2.8 fold downregulation), however it was not 
significant.  
A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The cytokines and chemokines that passed statistical significance were CXCL1, CXCL2, CXCL13, 
CCL22, and SPP1. CXCL1 and CXCL2 are known to be secreted by macrophages for neutrophil 
recruitment in the presence of necrotic cells 46,47. This finding would suggest that pazopanib 
causes necrotic cell death, which attracts macrophages for neutrophil recruitment to the 
tumour. An interesting finding is the upregulation of CCL22 and SPP1 in the responder group. 
CCL22 is a chemokine that is typically secreted by M2 macrophages 48. CCL22 recruits T-
regulatory cells, which dampens the immune response. SPP1 also known as osteopontin has 
been found to promote melanoma growth, angiogenesis and invasion 49,50. Osteopontin levels in 
melanoma patients’ serum have been observed to increase with the stage of the disease, with its 
highest levels at stage IV 51. These two tumour promoting chemokines might be responsible for 
the short response duration to pazopanib. The role of CXCL13 in melanoma has not been well 
described; however, CXCL13 has been implicated in the progression of prostate cancer 52. 
 
Our interpretation of the qPCR and immunohistochemistry results suggests that melanoma cells 
could be rescued from TKI induced stress conditions by the presence of M2 macrophages. 
Responding tumours secrete a mix of tumour suppressing and tumour promoting cytokines and 
chemokines. As there were no responders at the end of the study, it would suggest that the 
inhibition of tumour promoting cytokines and chemokines could have added benefit. 
Therefore, strategies to inhibit tumour-associated macrophages are needed. Today, antibodies 
suppressing the macrophage population with an anti-M-CSF antibody like MCS110 from 
Novartis are in clinical trials. Currently, clinical trials with MCS110 in combination with 
checkpoint inhibitors are in preparation.  
Emactuzumab (RG7155) is a monoclonal antibody that inhibits CSF1R activation and was 
successfully used in patients with pigmented villonodular synovitis, which is a malignant 
disease driven by macrophages 53. These molecules should be investigated in combination with 
multi-kinase inhibitors in order to overcome macrophage mediated tumour cell protection. 
In conclusion, pazopanib had limited efficacy in this patient population. M2-like macrophage 
density was associated with poor response and increased cytokine and chemokine expression 
was associated with early response. 
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Statement of Significance 
What’s already known about this topic? 
- Increased expression of VEGF and other tyrosine kinases leads to tumours promotion, 
associated with poor prognosis in patients with melanoma. 
- Pazopanib is a multi-target TKI effective in several tumour types suggested to suppress 
VEGF effects and has shown some efficacy in melanoma. 
 
What does this study add? 
- Pazopanib showed limited activity in advanced melanoma patients 
- Responding tumours demonstrate high expression of several chemokines and cytokines  
- Resistant tumours show high numbers of tumour associated M2-like macrophages 
ClinicalTrials.gov Identifier: NCT 01666418 
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TABLES 
Table 1: Demographics, tumour characteristics and treatment course of the individual patient.  
 
Pat. 
Nr. 
Gen
der 
Age 
AJCC 
Stage at 
baseline 
TNM stage 
(according 
to AJCC 
staging and 
classificatio
n) 
Pre-treatments # 
 
 
 
 
 
 
 
 
 
 
BRA
F 
Stat
us 
NRAS 
Status
Other 
Mutat
ions 
LDH 
≥ 
480
U/l 
at 
base
line 
* 
S100 
≥ 
0.2μg
/l at 
baseli
ne ** 
PERCIST 
day 10 of 
reference 
metastasis
PERCIST 
day 70 of 
reference 
metastasis
PERCIST 
of all 
metastase
s day 70 
Time 
on 
Treatm
ent (nr. 
of 
days) 
Reason 
for 
disconti
nuation 
1 M 86 IV M1a 1. DTIC 
2. Ipilimumab 
wt wt  Y Y SMD   62 AE 
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2 F 82 IV M1c 1. DTIC 
2. Ipilimumab 
3. Vindesine 
wt wt  Y N PMD PMD PMD 70 PD 
3 F 69 IV M1c 1. Hyperthermic Isolated 
Limb Perfusion (TNF, 
Melphalan) 
wt wt  Y N    5 AE 
4 M 60 IV M1b  wt wt  N N    48 PD 
5 M 76 IV M1b  wt wt  N N PMR   30 AE 
6 M 92 IV M1b  wt wt  N N    15 AE 
7 F 72 IV M1c 1. Temozolomide 
2. Ipilimumab 
wt wt  Y Y PMR   21 AE 
8 M 65 IV M1c 1. Peginterferon alpha-2b 
2. Pasireotide 
wt wt  Y N SMD PMR SMD 70 AE 
9 M 88 IV M1b  wt wt c-Kit 
572_5
75del
DPTQ
insE 
N N PMR   37 AE 
10 F 53 IV M1a 1. Ipilimumab 
2. MEK 162 + RAF 265 
wt wt  N N PMR SMD SMD 177 PD 
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3. Temozolomide 
11 M 75 IV M1c  wt NRAS 
Q61R 
 Y Y SMD   45 AE 
12 M 56 IV M1c 1. Adjuvant interferon 
therapy 
2. Ipilimumab 
3. Pembrolizumab 
wt NRAS 
Q61R 
 Y Y SMD PMR SMD 174 PD 
13 M 61 IV M1c 1. Interferon alpha 
2. DTIC 
3. Binimetinib 
wt NRAS 
Q61K
 Y Y PMR PMD SMD 120 PD 
14 M 59 IV M1c 1. Binimetinib 
2. Ipilimumab 
wt NRAS 
Q61R 
 Y Y SMD SMD SMD 162 PD 
15 M 55 IV M1c 1. Adjuvant Interferon 
alpha-2b 
2. Ipilimumab 
wt Wt  Y Y PMD   17 AE 
16 M 65 IV M1c  wt Wt  Y N PMD SMD PMD 70 PD 
17 F 71 III IIIC  wt wt   Y PMD PMD PMD 70 PD 
 
Abbreviations: 
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AJCC, American Joint Committee on Cancer. DTIC, Dacarbazine. wt, wildtype. Y, yes. N, no. 
 
Metabolic response according to PERCIST 1.0 criteria: CMR, Complete Metabolic Response. PMR, Partial Metabolic Response. SMD, Stable Metabolic Disease. 
PMD, Progressive Metabolic Disease. AE, Adverse Event. PD, Progression of Disease. 
 
# Pre-treatment indication is limited to systemic therapies. 
* Lactate dehydrogenase (LDH) upper normal range: ≥ 480U/l. 
** S100 ≥ 0.2μg/l 
Patients in bold: 8 patients further analysed 
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Table 2: The safety population included 17 patients that received at least one dose of study 
drug. Listed are all adverse events grade 3 and 4. 
 
Adverse Events in 17 Patients     
Adverse Event Number of patients Relationship to study medication  
Wound Infection      
Grade 3  1 Related  
Grade 4  -   
Pneumonia     
Grade 3  1 Not related *¹ 
Grade 4  -   
Dyspnea     
Grade 3  1 Not related *² 
Grade 4  -   
Delirium      
Grade 3  1 Not related *³ 
Grade 4  1 Not related *³ 
Neutropenia     
Grade 3  -   
Grade 4  3 Related  
Fatigue     
Grade 3  1 Related  
Grade 4  -   
Elevated Liver parameters     
Grade 3  3 Related  
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Grade 4  -   
Dysgeusia     
Grade 3  1 Related  
Grade 4  -   
Pain      
Grade 3  1 Not related *¹ 
Grade 4  -   
*¹ Tumour related *² Pre-existing *³ Related to urinary infection  
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Table 3: Changes of SUV value in the reference metastasis during study course. Specification in 
per cent (%), referring to baseline value. 
 
 Baseline Day 10 Day 70 
Responders 0 -82.1 -96.1 
 0 -75.7  
 0 -72.7  
 0 -67.8  
 0 -39.7 106.0 
Non-Responders 0 -28.6 -31.3 
 0 -26.6 -45.1 
 0 -12.0  
 0 5.9 29.7 
 0 14.7  
 0 30.4 -7.5 
 
0 37.9 
54.7 
 
 0 41.0  
 0 45.3  
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Table 4. Lactate Dehydrogenase (LDH) and S100 levels of responders and non-responders. 
 Day 0 Day 10 Day 70 
Responder (LDH) (n=5) 497.6 U/l (± 
95.1) 
(n= 4) 680.2 U/l (± 
199) 
(n=2) 501.5 U/l (± 
231.2) 
Non-responder 
(LDH) 
(n=8) 729.0 U/l (± 
75.93) 
(n=9) 796.3 U/l 
(±157) 
(n=5) 633.0 U/l (± 
204.8) 
Responder (S100) (n=5) 1.6 μg/l (± 0.75) (n=4) 0.3 μg/l  
(± 0.23) 
(n=1) 0.1 μg/l 
Non-responder 
(S100) 
(n=9) 4.4 μg/l (± 1.94) (n=9) 4.5 μg/l  
(± 2.37) 
(n= 5) 1.3 μg/l (± 1.5) 
 
Figure Legends: 
 
Fig. 1A: Study design of the trial.  Doses of Pazopanib (400 mg twice a day) were administered 
from day 1 to 10 and from day 14 to day 70. Intravenous Paclitaxel (150mg/m2 body surface) 
was given on day 14, 35 and 56. Evaluation of PET/CT (Positron emission tomography-
computer tomography), blood and biopsy samples was processed before treatment (baseline), 
after treatment with pazopanib and after treatment with pazopanib and paclitaxel. In between 
the two treatment regimens, patient passed through a 4-day washout phase. 
 
Fig. 1B: Flowchart of patient disposition.   
 
Fig. 2A: Representative PET/CTs of a responder and a non-responder patient before and after 
treatment with pazopanib (day 0, day 10). Non-responder: PET/CT images with disseminated 
disease, reference metastasis localized in the left lower leg. Responder: PET/CT images with 
reference metastasis in the left shoulder. 
 
Fig. 2B: Waterfall plot showing the percentage of SUV difference between day 0 and day 10 in 
target lesion. In red, non-responding patients. In blue, responding patients. Reference bar 
indicating the 30% reduction of SUV, standing for partial metabolic response (PMR). 
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Fig. 2C: Spider plot displaying the SUV changes of each target lesion in the course of the study at 
day 0, day 10 and day 70. 17 patients had a measurement at day 0 and only 8 remained at day 
70. 3 patients had PMR, 3 patients with stable metabolic disease (SMD), and 2 patients with 
progressive metabolic disease (PMD).  
 
Fig. 3A: Progression-free survival of all patients. Black curve: All patients included. Green curve: 
Responder group. Red curve: Non-responder group. The responders had a median progression 
free survival time of 149 days and the non-responders had a median progression free survival 
time of 70 days (p = 0.17) 
 
Fig. 3B: Overall survival of all patients. Black curve: All patients included. Green curve: 
Responder group. Red curve: Non-responder group. The responders had a median survival time 
of 494 days and the non-responders had a median survival time of 208 days (p=0.31).  
 
Fig. 3C: Lactate dehydrogenase (LDH) levels of responders and non-responders through the 
course of the study. Red boxes: responder group. White boxes: non-responder group.  
 
Fig. 3D: S100 levels of responders and non-responders through the course of the study. Red 
boxes: responder group. White boxes: non-responder group. 
 
Fig. 4A: Histology and immunohistochemistry of a reference metastasis. First row: H&E 
(Haematoxylin and eosin) stainings, second row: CD68, third row: CD163, fourth row: CD8. 
Scale bar = 100μM. 
 
Fig. 4B. Quantification of CD68, CD163, and CD8 stainings of the 8 patients analysed 
 
Fig. 5A: Bar graph representing the 84 chemokine and cytokine expression changes at day 10 
after treatment with Pazopanib. Blue bars represent the responder group and red bars 
represent the non-responder group. 
 
Fig. 5B: Bar graph of the 5 out of 84 significantly upregulated cytokine and chemokines after 
treatment with Pazopanib. 
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